NCT02174419 - Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Prurigo NodularisNodularis PrurigoPrurigoPruritus

Interventions

DRUG

nalbuphine HCl ER tablets 90 mg BID

nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks

DRUG

nalbuphine HCl ER tablets 180 mg BID

nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks

DRUG

Placebo tablets BID

Placebo tablets BID administered for 10 weeks

Trial Locations (4)

Temple University Hospital, Philadelphia

Case Western Reserve University, Cleveland

University of Münster, Münster

Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu, Wroclaw